<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="848">
  <stage>Registered</stage>
  <submitdate>16/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <nctid>NCT00199901</nctid>
  <trial_identification>
    <studytitle>Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma</studytitle>
    <scientifictitle>Randomized, Double-blind Phase II Trial of NY-ESO-1 ISCOMATRIX® Vaccine and ISCOMATRIX® Adjuvant Alone in Patients With Resected Stage IIc, III or IV Malignant Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LUD2003-009</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - NY-ESO-1 ISCOMATRIX®
Other interventions - ISCOMATRIX® adjuvant

Active Comparator: Vaccine - NY-ESO-1 ISCOMATRIX® vaccine

Placebo Comparator: Adjuvant Alone - ISCOMATRIX® adjuvant alone


Other interventions: NY-ESO-1 ISCOMATRIX®
100 µg of NY-ESO-1 protein formulated with 120 µg of ISCOMATRIX® adjuvant.
Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).

Other interventions: ISCOMATRIX® adjuvant
120 µg of ISCOMATRIX® alone.
Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>- Rate of Relapse-free Survival at 18 months.</outcome>
      <timepoint>18 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>NY-ESO-1 immunity</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relapse-free Survival and Overall Survival</outcome>
      <timepoint>18 months +</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically proven malignant melanoma.

          -  Tumor expression of NY-ESO-1 antigen by immunohistochemistry.

          -  Fully resected AJCC stage IIc, IIIb, IIIc or IV melanoma.

          -  Within six months of surgery for melanoma.

          -  Full recovery from surgery.

          -  No immunotherapy or systemic adjuvant therapy for melanoma since most recent relapse
             and/or resection. (Previous adjuvant therapy accepted providing pt relapsed and
             resected after this.)

          -  Age 18 years or older.

          -  Able to give written informed consent.

          -  Vital laboratory parameters within normal range, or protocol specified ranges.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Other serious or significant illnesses.

          -  Resected cerebral metastases.

          -  Ocular melanoma.

          -  Other malignancy within last 3 years, except for treated non-melanoma skin cancer and
             cervical cancer in situ.

          -  Using immunosuppressive drugs.

          -  Anticoagulation.

          -  Known HIV positivity.

          -  Chemotherapy or radiation therapy in last four weeks (6 weeks for nitrosourea drugs).

          -  Not available for immunological and clinical follow-up assessments.

          -  Participation in prior clinical trial involving an investigational agent within last 4
             weeks.

          -  Previous isolated limb perfusion (ILP).

          -  Pregnancy or breastfeeding.

          -  Refusal or inability to use effective means of contraception for women of childbearing
             potential.

          -  Mental impairment that may compromise ability to give informed consent and to comply
             with study requirements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>111</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Sydney Melanoma Unit - Royal Prince Alfred Hospital - Camperdown (Sydney)</hospital>
    <hospital>Newcastle Melanoma Unit - Newcastle Mater Misericordiae Hospital - Newcastle</hospital>
    <hospital>Mater Medical Centre, Princess Alexandra Hospital - Woolloongabba (Brisbane)</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Austin Health (Ludwig Institute Oncology Unit) - Heidelberg (Melbourne)</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands (Perth)</hospital>
    <postcode>2050 - Camperdown (Sydney)</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>4102 - Woolloongabba (Brisbane)</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3084 - Heidelberg (Melbourne)</postcode>
    <postcode>6009 - Nedlands (Perth)</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northwood</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Ludwig Institute for Cancer Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Institute of Cancer Research, United Kingdom</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to assess whether treatment with NY-ESO-1 ISCOMATRIX® vaccine
      improves outcomes for people with Malignant Melanoma which has been removed, but is at high
      risk of relapse.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00199901</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof. Jonathan S Cebon, MBBS PhD</name>
      <address>Ludwig Institute for Cancer Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>